Update from Lexeo Therapeutics
In a press release today, March 24, 2025, Lexeo Therapeutics reported their Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights.
Regarding their gene therapy program, LX2006 for the treatment of FA cardiomyopathy, the company reported further alignment on their development pathway following a meeting with the U.S. Food and Drug Administration (FDA). A pivotal study is planned, including adult and pediatric cohorts (both adolescents and children), and the use of prospective natural history data as external control.
The company also plans to provide a mid-year clinical update with safety and tolerability data, pre- and post-treatment cardiac frataxin protein expression, and clinical biomarker data from the ongoing Phase I SUNRISE-FA and Weill Cornell clinical trials.
